• In late April 2026, Option Care Health, Inc. reported first-quarter 2026 results showing sales of US$1,350.65 million and net income of US$45.34 million, while updating full-year 2026 net revenue guidance to a range of US$5.68 billion to US$5.78 billion amid headwinds in its chronic therapy segment.
• The guidance cut, coming shortly after a prior reaffirmation, has prompted multiple securities law investigations and raised questions about management’s visibility into patient census trends and therapy mix shifts.
• We’ll now examine how the reduced 2026 revenue guidance and chronic therapy challenges may influence Option Care Health’s longer-term investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Option Care Health Investment Narrative Recap

To own Option Care Health, you need to believe in the long term demand for home and alternate site infusion and the company’s ability to balance growth across acute and chronic therapies. The key short term catalyst is whether management can stabilize chronic inflammatory disease volumes and therapy mix after the Q1 reset, while the biggest risk is that payer and therapy mix shifts keep pressuring revenue and margins beyond what the new 2026 guidance range implies.

Against this backdrop, the Q1 2026 guidance cut to US$5.675 billion to US$5.775 billion stands out as the most relevant development. It crystallizes how chronic therapy headwinds can quickly change the outlook and has already triggered multiple securities law investigations, making execution on chronic census rebuilding and payer relationships even more central to how the next few quarters are judged.

Yet investors should be aware that the real concern may be how recurring therapy mix resets could affect revenue quality and earnings resilience over time...

Option Care Health's narrative projects $6.9 billion revenue and $302.9 million earnings by 2029.

Uncover how Option Care Health's forecasts yield a $30.73 fair value, a 48% upside to its current price.

Exploring Other Perspectives

The lowest estimate analysts were already cautious, assuming revenue of about US$6.7 billion and earnings near US$295.7 million by 2029, and the Q1 chronic reset plus roughly US$55 million gross profit headwind could push their more pessimistic view on biosimilar and therapy mix risks even further, so it is worth comparing how your own expectations stack up against these weaker assumptions.

Explore 2 other fair value estimates on Option Care Health - why the stock might be worth as much as 48% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Option Care Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Option Care Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Option Care Health's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 33 companies in the world exploring or producing it. Find the list for free.
• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.